Urinary Tract Infections in Patients with Ureteral Stents
Introduction to Treatment
- The European Association of Urology recommends a 2 gm dose of ceftriaxone for complicated UTIs, which achieves sufficient free plasma concentration to treat even resistant strains 2
- Ceftriaxone 2 gm IV is sufficient for treating a urinary tract infection in a patient with a ureteral stent, as this dosage has been shown to effectively cover common uropathogens and reduce serious post-procedural sepsis-related complications from 50% to 9% in high-risk patients 1
- Up to 50% of ureteral stent infections can be polymicrobial, requiring broad-spectrum coverage that ceftriaxone provides 1
Administration and Monitoring
- Once-daily dosing of ceftriaxone is appropriate for stent-associated infections 1
- Clinical improvement should be evident within 48-72 hours, and consider imaging if no improvement after 72 hours 2
- Obtain cultures before initiating therapy if possible, to guide targeted therapy if initial empiric treatment fails
Alternative Therapies
- For ceftriaxone-resistant infections, options include ertapenem 1 gm IV daily 3
- Piperacillin/tazobactam 2.5-4.5 g TID is an alternative therapy for ceftriaxone-resistant infections 2
- Carbapenems can be used for multidrug-resistant organisms 2